BSE filing, NSE: FREDUN. Summary written from the filing by ALFA Finder's alert engine.
Fredun Pharmaceuticals Ltd: key numbers
- Share price
- ₹1,366.05
- Market cap
- ₹1,957 Cr
- Revenue (annual)
- ₹635.5 Cr
- Net profit (annual)
- ₹32.62 Cr
- P/E (TTM)
- 44.7×Sector 45.9×
- Promoter holding
- 43.62%-0.95% QoQ
- FII holding
- 0.69%Current quarter
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
More from Fredun Pharmaceuticals Ltd
All →Fredun Pharmaceuticals Convertible Warrants
Fredun Pharmaceuticals allotted 44,000 equity shares to three non-promoter investors on conversion of 14,667 warrants. The conversion follows the 1:2 bonus issue, which adjusted warrant entitlements.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending September 30, 2026. The disclosure provides the equity holding structure for shareholders.
Fredun Pharmaceuticals Other Announcement
Fredun Pharmaceuticals filed a compliance certificate under Regulation 74(5) of the SEBI (DP) Regulations, 2018. It confirms the processing of dematerialized shares for the quarter.
Fredun Pharmaceuticals Business Update
Fredun Pharma announces strategic pet-care acquisitions, capacity expansion, and a 100% branded portfolio target by 2029. H1 FY27 business update outlines multi-pillar growth transformation.
- manufacturing infrastructure (Palghar plant)
- 90000 sq. ft.
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals allotted 1,82,400 equity shares upon the conversion of 60,800 warrants. The company received total consideration of ₹7.60 Crore for this warrant conversion.
- Value
- ₹7.60 Cr
Fredun Pharmaceuticals Capital Structure Change
Fredun Pharmaceuticals has allotted 1,82,400 equity shares following the conversion of 60,800 warrants into equity shares, completing the preferential issue conversion process.
Other board meeting date announcements
All →Sanco Trans Board Meeting Date
Sanco Trans scheduled a November 12, 2026 board meeting to consider unaudited half-year results for September 2026. The trading window is closed until November 16, 2026.
Auro Laboratories Board Meeting Date
Auro Laboratories scheduled a November 13, 2026 board meeting to approve unaudited September quarter results. The trading window stays closed until 48 hours after the meeting.
Abril Paper Tech Board Meeting Date
Abril Paper Tech will hold a board meeting on 5 November 2026 to consider unaudited half-year results for September 2026. The trading window stays closed until 48 hours after the results are released.
SJP Ultrasonics Board Meeting Date
SJP Ultrasonics intimated BSE of a board meeting on November 5, 2026 to approve unaudited half-year results and limited review report. Trading window reopens November 7, 2026, 48 hours after results.
Ambica Agarbathies & Aroma Industries Board Meeting Date
Ambica Agarbathies & Aroma Industries has notified a board meeting on 5 November 2026 to consider unaudited financial results for the quarter and half year ended 30 September 2026. The filing is an advance intimation, with the results not yet approved.
Minal Industries Board Meeting Date
Minal Industries scheduled a board meeting on November 05, 2026 to approve unaudited standalone and consolidated results for Q2 and H1 ended September 30, 2026. The trading window stays closed until 48 hours after the results declaration.